Scleromyxedema is a rare, mucinous skin disorder of unknown origin, one of a number of conditions that mimic systemic sclerosis. Although cases of scleromyxedema remain rare, a better understanding of its mechanisms of action could have implications for the research and treatment of scleroderma and related autoimmune conditions, says Laura K. Hummers, MD, ScM, co-director…
An antibody previously un-recognized in patients with Sjögren’s syndrome may shed new light on the pathophysiology of one of the most troubling and disabling symptoms in many of these patients. Investigators at Johns Hopkins University, Baltimore, found the anti-calponin 3 antibody had a high specificity for Sjögren’s syndrome, particularly among patients with neuropathies.1 “There is…
During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…
Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…
Sjögren’s syndrome is a chronic multi-system autoimmune disease characterized by inflammation and subsequent destruction of exocrine glands. Sjögren’s syndrome can present with glandular or extra-glandular manifestations. Neuromyelitis optica spectrum disorder (NMOSD) is a rare central nervous system (CNS) autoimmune disease that can present as the initial manifestation in less than 5% of patients with Sjögren’s….
CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…
Mirtazapine has been prescribed off-label to fibromyalgia patients who have not responded to other treatments. However, a recent systemic review found no difference between mirtazapine and placebo for these patients, and any potential benefits from mirtazapine may not outweigh its potential harm, including drowsiness, weight gain and liver damage…
Over time, systemic lupus erythematosus (SLE) can lead to considerable organ damage. Preventing this outcome is complicated by a scarcity of treatment options that can drive the disease into remission and by the side effects of existing therapies, such as prednisone and other corticosteroids, which may themselves contribute to the long-term damage. The largest study…
Systemic lupus erythematosus (SLE) is a heterogeneous, autoimmune, inflammatory, connective tissue disease affecting multiple organs. Neither central nervous system nor peripheral nervous systems are spared. The neurologic system is involved in a wide range of 10–80% of patients with SLE. Peripheral neuropathy, such as Guillain-Barré syndrome (GBS) and its variants, can occur in neurologic complications…
I glanced up from Amanda Wolf’s chart as the emergency department nurse, followed by the lab technician (tech), followed by the electrocardiogram (ECG) tech flowed into cubicle No. 5. John Benner, MD, pulled up a chair to review the case with me at the nursing station. “Here’s what we’ve got. Thirteen-year-old girl with a one-week…